CAT

860.57

-0.38%↓

284.83

-0.46%↓

GEV.US

1,011.44

-0.21%↓

RTX

174.52

-0.85%↓

214.86

-2.66%↓

CAT

860.57

-0.38%↓

284.83

-0.46%↓

GEV.US

1,011.44

-0.21%↓

RTX

174.52

-0.85%↓

214.86

-2.66%↓

CAT

860.57

-0.38%↓

284.83

-0.46%↓

GEV.US

1,011.44

-0.21%↓

RTX

174.52

-0.85%↓

214.86

-2.66%↓

CAT

860.57

-0.38%↓

284.83

-0.46%↓

GEV.US

1,011.44

-0.21%↓

RTX

174.52

-0.85%↓

214.86

-2.66%↓

CAT

860.57

-0.38%↓

284.83

-0.46%↓

GEV.US

1,011.44

-0.21%↓

RTX

174.52

-0.85%↓

214.86

-2.66%↓

Начало・Списък с акции・Ocugen Inc

Ocugen Inc

Отворен

1.29 -3.01

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.28

Максимум

1.34

Ключови измерители
By Trading Economics
Приходи	-1.5M -19M
Продажби	1.7M 1.5M
EPS	-0.06
Марж на печалбата	-1,250.946
Служители	116
EBITDA	-987K -17M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+732.37% upside

Дивиденти
By Dow Jones
Следващи печалби	31.07.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-125M 501M
Предишно отваряне	4.3
Предишно затваряне	1.29

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

0.6818 / 0.74 Подкрепа & съпротива

Ocugen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

18.05.2026 г., 23:10 ч. UTC

Горещи акции

Stocks to Watch: Agilysys, XP

18.05.2026 г., 18:44 ч. UTC

Значими двигатели на пазара

Claritev Shares Recover After Comments About DOJ

18.05.2026 г., 23:55 ч. UTC

Печалби

Review & Preview: Earnings' Last Gasp -- Barrons.com

18.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

18.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18.05.2026 г., 23:37 ч. UTC

Пазарно говорене

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18.05.2026 г., 22:31 ч. UTC

Придобивния, сливания и поглъщания

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18.05.2026 г., 22:30 ч. UTC

Придобивния, сливания и поглъщания

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18.05.2026 г., 22:30 ч. UTC

Придобивния, сливания и поглъщания

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18.05.2026 г., 22:25 ч. UTC

Придобивния, сливания и поглъщания

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18.05.2026 г., 22:24 ч. UTC

Придобивния, сливания и поглъщания

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

18.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

18.05.2026 г., 20:25 ч. UTC

Печалби

Correct: XP 1Q Total Client Assets BRL1.53T

18.05.2026 г., 20:23 ч. UTC

Печалби

XP 1Q Total Client Assets BRL1.53B

18.05.2026 г., 20:19 ч. UTC

Печалби

XP 1Q Adj EPS BRL2.49 >XP

18.05.2026 г., 20:19 ч. UTC

Печалби

XP 1Q Rev BRL4.73B >XP

18.05.2026 г., 19:10 ч. UTC

Пазарно говорене

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18.05.2026 г., 19:00 ч. UTC

Печалби

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18.05.2026 г., 18:52 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18.05.2026 г., 18:17 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18.05.2026 г., 17:22 ч. UTC

Пазарно говорене

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18.05.2026 г., 16:57 ч. UTC

Придобивния, сливания и поглъщания

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18.05.2026 г., 16:57 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

18.05.2026 г., 16:57 ч. UTC

Пазарно говорене

Commodities Higher as Traders Want Physical Assets -- Market Talk

18.05.2026 г., 16:54 ч. UTC

Придобивния, сливания и поглъщания

Vinci Doesn't Set Out Financial Details of Deal

18.05.2026 г., 16:50 ч. UTC

Придобивния, сливания и поглъщания

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18.05.2026 г., 16:49 ч. UTC

Придобивния, сливания и поглъщания

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18.05.2026 г., 16:49 ч. UTC

Придобивния, сливания и поглъщания

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18.05.2026 г., 16:48 ч. UTC

Придобивния, сливания и поглъщания

Vinci Buys Canada's Modern Group of Companies

Сравнение с други в отрасъла

Ценова промяна

Ocugen Inc Прогноза

Ценова цел

By TipRanks

732.37% нагоре

12-месечна прогноза

Среден 11.57 USD 732.37%

Висок 22 USD

Нисък 7 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocugen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Ocugen Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.6818 / 0.74Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There are no events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.